Drug intelligence / Profile preview

HR19024

Development stage: Phase 1
Lead developer: Shanghai Hengrui Pharmaceutical Co., Ltd.
Administration: Injectable

Overview

HR19024 is an investigational drug being developed as an injectable therapy for the treatment of advanced solid tumors. It is currently undergoing clinical trials to evaluate its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors. The developer of HR19024 is Shanghai Hengrui Pharmaceutical. The specific mechanism of action and molecular target have not been disclosed in publicly available sources.

Beyond the preview

Go deeper on HR19024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HR19024.

Explore the full profile